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Several population pharmacokinetic models describe the dose-exposure relationship of tobramycin in pediatric patients. Before
the implementation of these models in clinical practice for dosage adjustment, their predictive performance should be externally
evaluated. This study tested the predictive performance of all published population pharmacokinetic models of tobramycin de-
veloped for pediatric patients with an independent patient cohort. A literature search was conducted to identify suitable models
for testing. Demographic and pharmacokinetic data were collected retrospectively from the medical records of pediatric patients
who had received intravenous tobramycin. Tobramycin exposure was predicted from eachmodel. Predictive performance was
assessed by visual comparison of predictions to observations, by calculation of bias and imprecision, and through the use of sim-
ulation-based diagnostics. Eight population pharmacokinetic models were identified. A total of 269 concentration-time points
from 41 pediatric patients with cystic fibrosis were collected for external evaluation. Three models consistently performed best
in all evaluations and hadmean errors ranging from0.4 to 1.8 mg/liter, relative mean errors ranging from 4.9 to 29.4%, and
root mean square errors ranging from 47.8 to 66.9%. Simulation-based diagnostics supported these findings. Models that al-
lowed a two-compartment disposition generally had better predictive performance than those that used a one-compartment dis-
position model. Several publishedmodels of the pharmacokinetics of tobramycin showed reasonable low levels of bias, although
all models seemed to have some problems with imprecision. This suggests that knowledge of typical pharmacokinetic behavior
and patient covariate values alone without feedback concentrationmeasurements from individual patients is not sufficient to
make precise predictions.
Tobramycin is an aminoglycoside antibiotic and one of themost effective antibiotics for the treatment of severe Gram-
negative bacterial infections (1). Tobramycin is particularly effec-
tive against Pseudomonas aeruginosa and is commonly used in
patients with cystic fibrosis (2). Tobramycin exhibits concentra-
tion-dependent bactericidal action, whereby higher drug concen-
trations are correlated with a greater magnitude and a higher
speed of bacterial eradication (3, 4). Treatment success and a de-
creased incidence of antibiotic resistance have been correlated
with a ratio of the peak (maximum) tobramycin concentration
(Cmax) to the MIC of7 to 10 (5, 6) and a ratio of the area under
the concentration-time curve (AUC) to the MIC of80 (7, 8). A
prolonged high level of exposure to tobramycin and, in particular,
sustained, elevated trough (minimum) serum concentrations
(Cmin) have been associatedwith significant adverse effects (9, 10),
such as nephrotoxicity, which is typically reversible, and ototox-
icity, which can be permanent and result in hearing loss (4). Con-
sequently, tobramycin dosing aims to achieve a sufficiently high
Cmax and AUC for effective bactericidal activity while producing a
sufficiently low Cmin to minimize the potential for toxicity (11)
and the emergence of resistant microorganisms (12).
Furthermore, tobramycin has a narrow therapeutic window
and displays a high level of pharmacokinetic variability (11). This
variability is particularly increased in pediatric patients, if great
changes in maturation, body size, and renal function over a short
time frame are not accounted for (13). As a result, if treatment for
more than 48 h is required (14), some guidelines recommend
computerized therapeutic drug monitoring with Bayesian fore-
casting software programs (15, 16). Suchmethods are increasingly
being used in practice (17). Bayesian forecasting methods use a
priori pharmacokinetic parameters from a suitable population
model and current concentration observations to estimate each
patient’s exposure (15, 18, 19). A suitable population model that
characterizes average exposure after drug administration, along
with pharmacokinetic variability and the influence of patient co-
variate factors, such as the patient’s age, weight, and creatinine
clearance (CLCR), on pharmacokinetic parameters, is required
(20–22). Before a population pharmacokinetic model can be con-
fidently used in clinical practice in a Bayesian forecasting com-
puter program, it must be adequately validated (23). Model vali-
dation seeks to quantify the reproducibility and accuracy of a
model (24). Themost robust form of validation is external valida-
tion, which involves the collection of data from a new patient
cohort receiving the drug and assessment of the predictive perfor-
mance of the model (23, 24).
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This study aimed to identify and compare population pharma-
cokineticmodels of intravenous tobramycin previously published
in the literature and externally validate these models by applying
them to a new patient cohort to assess their predictive perfor-
mance. The overarching goal of the study was to find suitable
models to aid computerized therapeutic drug monitoring.
MATERIALS AND METHODS
Literature search. A search of the literature in the databases PubMed,
Medline, and EMBASE was performed, and published models of the
population pharmacokinetics of tobramycin were identified. The
search was conducted from February to March 2016 using the termi-
nology “tobramycin,” “pharmacokinetics,” and “intravenous” and/or
“population pharmacokinetics,” “nonlinear mixed effects modeling,”
and “NONMEM.” A manual search for population models was also con-
ducted by inspecting the bibliographies of relevant journal articles. No
restriction was placed on the study publication date; the study language
was limited to English. Population models were included in this study if
they had been developed with data from humans and included data from
pediatric patients, the pharmacokinetic analyses had involved a compart-
mental approach, and themajority of concentration-time pointsmodeled
(50%) were based on measurements for tobramycin, as opposed to
other aminoglycosides. Populationmodels were excluded from the exter-
nal validation if not enough informationwas provided for themodel to be
fully reproducible in terms of typical parameter values or covariate rela-
tionships or the residual unexplained variability (RUV) reported was
above 50%.
Patients and validation data collected. Pharmacokinetic and demo-
graphic data were collected retrospectively from the medical records of
pediatric patients with cystic fibrosis who received treatment with intra-
venous tobramycin at the Lady Cilento Children’s Hospital in Brisbane,
Australia. This study was approved by the Ethics Committees of the Uni-
versity of Queensland (approval number 2012001415) and Lady Cilento
Children’s Hospital (approval number HREC/12/QHC75). No patient
data in the external validation data set had previously been included in the
development of any of the models. The pharmacokinetic data recorded
included the tobramycin dose administered, the time of dosing, the infu-
sion time and rate, tobramycin plasma concentrations, and the times at
which serum samples were taken for measurement of the tobramycin
concentration. Data were included if at least one intravenous dose of
tobramycin and the respective concentration-time measurement were
available. The demographic data recorded included the following: patient
age, sex, weight, and height; the indication for tobramycin treatment; and
serum creatinine (SCR) concentrations.Missing SCRmeasurements were
replaced by an expected mean SCR concentration, based on the age and
gender of the patient, as described by Ceriotti et al. (25). SCR measure-
ments recorded as30mol/liter, which is below the limit of quantifica-
tion (LOQ), were replaced by a value of 29mol/liter. Data were excluded
from the analysis if there was uncertainty about the time of dosing or the
time of drug concentration measurement and if dosing information was
absent. An occasion was defined as a single tobramycin dosing interval.
Tobramycin concentrations were measured using fluorescence polariza-
tion immunoassays, which had a lower LOQ of 0.2 mg/liter. The within-
and between-assay coefficients of variation were below 10%.
Assessment of predictive performance. Each selected population
pharmacokinetic model was separately implemented in NONMEM (ver-
sion 7.3) (26) as described in the original article, and the output was
visually explored by the use of graphics produced by the Rstudio program
(version 0.99.484). Parameter values and covariate relationships for each
model were set to those determined in the publications, and predictions
were generated on the basis of the doses, sampling times, and covariate
values recorded in the validation data set. If the models did not report
between-subject variability (BSV) for the pharmacokinetic parameters or
RUV in the model, a BSV value of 30% for clearance was supplemented
and an additive error of 0.05 mg/liter and a proportional error of 20%
were supplemented for RUV. Formodels that included renal function as a
covariate, creatinine clearance (CLCR) was estimated from patient demo-
graphics in the validation data set according to the exactmethoddescribed
in each published study.
The predictive performance of each model was assessed visually by
comparing plots of the population predicted concentration (Cpred) and
the observed concentration (Cobs) to look for bias (a systematic upward or
downward deviation from the line of unity in these plots) and imprecision
(a high degree of scatter of data points around the line of unity) and numer-
ically through calculation of the mean error (ME; in milligrams per hour;
equation 1), the mean relative error (MRE; in percent; equation 2), and the
relative root mean squared error (RMSE; in percent; equation 3) (27).
ME
1
ni1
n
Cpred Cobs (1)
MRE
1
ni1
n Cpred CobsCobs  (2)
RMSE1ni1n Cpred CobsCobs 
2
(3)
Predicted performance was also assessed by the use of simulation-
based diagnostics. Visual predictive check (VPC) (28) plots were gener-
ated on the basis of 1,000 Monte Carlo simulations by applying the liter-
ature models and by using the validation data set design. The 10th and
90th percentiles of the simulated and validation data were plotted versus
time after dosing, and the plots were compared visually for model devia-
tions from the validation data. Plots of the normalized prediction distri-
bution error (npde) versus time after dosing were also generated on the
basis of 1,000Monte Carlo simulations of the validation data set’s patient
dosage history and covariate values. The mean, variance, skewness, and
kurtosis of the npde values were calculated and examined statistically
(29, 30).
RESULTS
Literature search. Figure S1 in the supplemental material shows
the steps involved in the literature search. Seven studies describing
a total of eight population pharmacokineticmodels of tobramycin
were deemed appropriate for external validation. The models
were numbered from 1 to 8 and are referred to asM1 toM8. Table
1 provides a summary of the key information about the published
population pharmacokinetic models of tobramycin that were ex-
amined. Two models were developed with data from both adults
and pediatric patients (age, 18 years), and six models were de-
veloped only with data from pediatric populations. The largest
model was developed with data from 732 adults and pediatric
patients with and without cystic fibrosis and 5,605 samples in
which the tobramycin concentration was determined, while the
smallest model was developed with data from 35 cystic fibrosis
patients providing 318 concentration samples in a mainly pediat-
ric population (0.5 to 17.9 years). All models were based on intra-
venous administration of tobramycin with first-order linear elim-
ination. Five models were developed solely with data from cystic
fibrosis patients, one was developed with data from patients with
and without cystic fibrosis, and the remaining model was devel-
oped with data from general population patients, neonates, and
patients with severe infections or in an intensive care unit (ICU).
While some models included data from patients with moderate
renal impairment, the average renal function in each study popu-
lation was normal to mildly reduced.
The disposition of tobramycin was described by a one-com-
partment distribution in fivemodels (62.5%) and a two-compart-
ment distribution in three models. However, a trend toward the
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3408 aac.asm.org June 2016 Volume 60 Number 6Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 25, 2016 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
T
A
B
LE
1
Su
m
m
ary
of
pu
blish
ed
m
odels
of
th
e
popu
lation
ph
arm
acokin
etics
of
tobram
ycin
for
extern
alvalidation
a
M
odeln
o.(referen
ce)
N
o.ofpatien
ts
(totaln
o.ofsam
ples)
A
ge
(yr)
W
t
(kg)
C
L
C
R
Stru
ctu
ral
m
odel
P
aram
eter
valu
es
an
d
covariate
relation
sh
ips
in
clu
ded
B
SV
(%
)
(B
O
V
[%
])
R
U
V
A
du
lts
an
d
pediatric
patien
ts
M
1
( 32)
136
C
F
patien
ts
(N
R
)
5–50
b
15–82
b
30–148
m
l/m
in
b
1
C
M
T
k
el (h

1)

0.01

0.00294

C
L
C
R
N
R
N
R
C
L
(liters/h
)

V

k
el
V
(liters)

0.335

w
t
M
2
(36)
732
C
F
an
d
gen
eral
patien
ts
(5,605)
0.01–85.0
b
3.3–120.0
b
34–145
m
l/m
in
b
2
C
M
T
C
L
(fem
ale)
(liters/h
/70
kg)

8.08

(LB
W
/70)
0
.9
5
2

(1

[
0.021

(age

18)])

(m
ean
SC
R
/SC
R
)
0
.2
2
2
C
L

25.9
(12.7)
P
rop

20.4%
C
L
(m
ale)
(liters/h
/70
kg)

9.39

(LB
W
/
70)
0
.9
5
2

(1

[
0.021

(age

18)])

(m
ean
SC
R
/SC
R
)
0
.2
2
2
V
1

15.2
V
1
(fem
ale)
(liters/70
kg)

20.1

(LB
W
/70)
Q

41.8
V
1
(m
ale)
(liters/70
kg)

25.1

(LB
W
/70)
V
2

58.5
V
2
(liters/70
kg)

9.98

(LB
W
/70)
Q
(liters/h
/70
kg)

1.5

(LB
W
/70)
0
.9
5
2
M
3
(33)
44
C
F
patien
ts
(329)
13.4
(0.75–20)
c
39
	
14.6
N
R
1
C
M
T
C
L
(liters/h
)

0.103

w
t 0
.7
5
N
R
N
R
V
(liters)

0.267

w
t
P
ediatric
patien
ts
M
4
( 32)
85
C
F
patien
ts
(N
R
)
10.0
(5–15)
c
34.0
(15–78)
c
80
m
l/m
in
(30–128
m
l/m
in
)
c
1
C
M
T
k
el (h

1)

0.01

0.00281

C
L
C
R
N
R
N
R
C
L
(liters/h
)

V

k
el
V
(liters)

0.363

w
t
M
5
(31)
140
n
eon
ates
w
ith
severe
in
fection
s
(365)
0.012
	
0.008
(0.003–0.044)
d
2.75
	
0.76
(0.8–4.25)
d
0.76
	
0.19
m
g/dl
(0.04–1.20
m
g/dl)
e
1
C
M
T
C
L
(liters/h
)

0.0508

w
t f
C
L

25.8
P
rop

19.2%
V
(liters)

0.533

w
t
V

21.9
M
6
( 11)
35
C
F
patien
ts
(318)
9.5
(0.5–17.9)
c
34
(6.0–72.6)
c
106
m
l/m
in
(23–195
m
l/m
in
)
c
2
C
M
T
C
L
(liters/h
/70
kg)

6.37

(w
t/70)
0
.7
5
C
L

11.7
(6.5)
P
rop

19.0%
V
1
(liters/70
kg)

18.7

(w
t/70)
V
1

11.7
Q
(liters/h
)

0.39
V
2

42.0
V
2
(liters)

1.32
M
7
(3)
257
C
F
patien
ts
(2,015)
8.1
(4.6–13.9)
g
23.9
(16.3–42.6)
g
0.5
m
g/dl
(0.4–0.6
m
g/dl)
h
1
C
M
T
C
L
(liters/h
)

5.59

(w
t/70)
0
.7
5
C
L

22.8
P
rop

19.1%
V
(liters)

18.90

(w
t/70)
V

11.2
A
dd

1.4
m
g/liter
M
8
( 41)
614
IC
U
patien
ts
(1,273)
0.008
(0–18)
c
2.01
(0.485–85)
c
0.81
m
g/dl
(0.13–1.17
m
g/dl)
i
2
C
M
T
C
L
(liters/h
)

0.28

(w
t/4)
B
D
E
C
L

39.7
P
rop

29.8%
B
D
E

2.23

w
t 
0
.0
6
5
A
dd

0.05
m
g/liter
V
1
(liters)

1.9

(w
t/4)
0
.7
3
5
Q
(liters/h
)

C
L
V
2
(liters)

V
1
a
A
dd,additive
residu
alu
n
explain
ed
error;B
D
E
,body
w
eigh
t-depen
den
t
expon
en
t;B
O
V
,betw
een
-occasion
variability;B
SA
,body
su
rface
area;B
SV
,betw
een
-su
bject
variability;C
F,cystic
fi
brosis;C
L,totalbody
clearan
ce;C
L
C
R ,
creatin
in
e
clearan
ce
(m
illiliters
per
m
in
u
te);C
M
T
,distribu
tion
com
partm
en
t;C
V
,coeffi
cien
t
ofvariation
;G
FR
,glom
eru
lar
fi
ltration
rate
calcu
lated,as
described
by
M
an
ju
n
ath
et
al.(44);IC
U
,in
ten
sive
care
u
n
it;k
el ,elim
in
ation
rate
con
stan
t;LB
W
,lean
body
w
eigh
t
(in
kilogram
s);N
R
,n
ot
reported;P
rop,proportion
alresidu
alu
n
explain
ed
error;Q
,typicalin
tercom
partm
en
talclearan
ce;R
U
V
,residu
alu
n
explain
ed
variability;V
,apparen
t
volu
m
e
ofdistribu
tion
;
V
1 ,typicalvolu
m
e
ofth
e
cen
tralcom
partm
en
t;V
2 ,typicalvolu
m
e
ofth
e
periph
eralcom
partm
en
t.
b
T
h
e
m
edian
or
m
ean
on
ly
w
as
reported
separately
for
pediatric
patien
ts
an
d
adu
lts
an
d
w
as
n
ot
reported
for
th
e
data
com
bin
ed.V
alu
es
represen
t
th
e
ran
ge
ofvalu
es
obtain
ed.
cD
ata
represen
t
th
e
m
ean
(ran
ge).
d
D
ata
represen
t
th
e
m
ean
	
stan
dard
deviation
(ran
ge).
e
D
ata
represen
t
th
e
m
ean
	
stan
dard
deviation
(ran
ge)
seru
m
creatin
in
e
con
cen
tration
.
fC
L
(liters
per
h
ou
r)

0.0508

0.843
ifth
e
birth
w
eigh
t
is

2.5
kg.
g
D
ata
represen
t
th
e
m
ean
(in
terqu
artile
ran
ge).
h
D
ata
represen
t
th
e
m
ean
(in
terqu
artile
ran
ge)
seru
m
creatin
in
e
con
cen
tration
.
iD
ata
represen
t
th
e
m
ean
(ran
ge)
seru
m
creatin
in
e
con
cen
tration
.
Validation of Population Pharmacokinetic Model of Tobramycin
June 2016 Volume 60 Number 6 aac.asm.org 3409Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 25, 2016 by UQ Library
http://aac.asm
.org/
D
ow
nloaded from
 
reporting of two-compartment models in more recent publica-
tions was noted. As a significant predictor of variability in tobra-
mycin clearance, 75% of the models included a measure of body
size (total body weight or lean body weight) and 37.5% of the
models included a measure of renal function (CLCR or SCR). All
models included ameasure of patient size as a significant predictor
of variability in the tobramycin volume of distribution (V), with
12.5% using lean body weight and all others using total body
weight. Other covariates reported to be significant in some studies
included the patient’s sex and age and low birth weight. Typical
values for tobramycin clearance in the studies ranged from 0.06 to
4.42 liters/h, with the lowest value being reported in studies per-
formed with neonates. In studies based on a one-compartment
model, the typical volume of distribution varied across different
subpopulations, ranging from 1.47 to 12.34 liters, with the lowest
values being reported in studies performed with neonates. In
models based on a two-compartmentmodel, the typical volumeof
the central compartment ranged from 1.15 to 2.83 liters, with
lower values being reported for neonates. Most models (62.5%)
estimated the BSV (coefficient of variation [CV], in percent) as-
sociatedwith tobramycin clearance, with values ranging from11.7
to 39.7%. The highest BSV in clearance was reported in a study
conducted with ICU patients. The between-occasion variability
(BOV) (CV) in clearance was reported in only two studies and
ranged from 6.5 to 12.7%. RUV (CV) was modeled using a pro-
portional or combined proportional/additive error model in
37.5% and 25% of models, respectively, with the values ranging
from 19.0 to 29.8% for the proportional component and 0.05 to
1.4 mg/liter for the additive component. Further information can
be found in Table 1. The majority (87.5%) of the models were
internally validated, most commonly using a log-likelihood ratio
test, goodness-of-fit plots, visual predictive checks, and/or a non-
parametric bootstrap. One study employed external validation by
using data from a new patient population (31). Six of the eight
models were developed using NONMEM software; the others
used MW/Pharm (32) and WinNonMix (33) software to develop
the population pharmacokinetic model.
Patient and validation data collected.The data used for exter-
nal evaluation were collected from 41 patients. A summary of the
key demographic and pharmacokinetic features of the patients
providing data for this data set is provided in Table 2. All children
in this population had cystic fibrosis. Themedian age, weight, and
height of the populationwere 2.2 years (interquartile range [IQR],
1.1, 4.9 years), 12.4 kg (IQR, 8.6, 21.0 kg), and 89.0 cm (IQR, 71.0,
112.0 cm), respectively. The majority of patients for whom data
were collected had normal renal function with a median CLCR of
90.6 ml/min/1.73 m2 (IQR, 71.7, 112.0 ml/min/1.73 m2), calcu-
lated using the modified Schwartz formula (34). Heights were not
recorded for two children, and their height was estimated using
average age-associated values fromWHO growth charts (35). For
five patients, SCR was measured greater than 3 months before or
after tobramycin administration, and in these instances, the
expected mean SCR was used (25). In total, data from 269
concentration-time points were available for external valida-
tion. No concentration measurements were below the assay
LOQ for tobramycin. Figure 1 displays these concentration
measurements versus time after dosing. Ninety-eight percent of
the tobramycin doses were administered as an intravenous infu-
sion over 30 min, with the other 2% of the doses being given over
45 to 60 min. In general, concentration measurements were ob-
tained at about 2 and 6 h after the dose was administered.
Assessment of predictive performance. Figure 2 displays the
observed versus the population predicted concentrations when
each selected population pharmacokinetic model was imple-
mented in NONMEM. Models 2, 6, and 7 exhibited the smallest
bias and imprecision in graphic comparisons of the predicted ver-
sus the observed concentrations. Graphical results were closely
mirrored in numerical estimates of the model predictive perfor-
mance presented in Table 3. Models 2, 6, and 7 were consistently
ranked as the top threemodels with the lowest values ofME,MRE,
and RMSE. Models 3 and 5 consistently obtained the highest val-
ues for these metrics. ME was found to be similar among the
TABLE 2 Key demographic and pharmacokinetic features of the
patients providing data for the external validation data seta
Characteristic Value(s)
Median (IQR) age (yr) 2.2 (1.1, 4.9)
No. of patients aged (yr):
2 20
2–12 19
12 2
No. of males/no. of females 24/17
Median (IQR) total body wt (kg) 12.4 (8.6, 21.0)
Median (IQR) ht (cm) 89.0 (71.0, 112.0)
Median (IQR) serum creatinine concn (mol/liter) 29 (30, 51)
Median (IQR) creatinine clearance (ml/min/1.73 m2)b 90.6 (71.7, 112.0)
No. of observations 269
Median (IQR) no. of sampling occasions/patient 6.6 (3, 11)
Median (IQR) dose (mg/kg) 11.3 (9.9, 12.5)
Median (IQR) time of sampling after dosing (h) 5.1 (2.1, 6)
Median (IQR) tobramycin concn (mg/liter) 6.1 (2.8, 15.2)
a Data are for 41 patients.
b Calculated using the modified Schwartz formula (34).
FIG 1 Tobramycin concentration versus time after dosing obtained with data
available for external validation of the identified models.
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models ranked as the top three, with the smallest ME, which was
for model 3, being 0.4 mg/liter (95% confidence interval [CI],
0.7, 0.01 mg/liter) for model 6. The overall highest ME was 12.1
mg/liter (95% CI, 11.4, 12.7 mg/liter). MREs were 4.9%, 19.2%,
and 29.4% for the models ranked as the top three. Overall, the
lowest MRE was 4.9% (95% CI, 0.8, 10.6%), which was for
model 6, and the highest MRE was 274.1% (95% CI, 240.4,
307.7%), which was for model 3. Overall RMSE values ranged
from 47.8% for model 6 to 392.4% for model 3.
Table 3, Fig. S2 in the supplemental material, and Fig. 3 illus-
trate the results from the simulation-based diagnostics. Models 2,
6, and 7 showed visually better VPC graphics than the other mod-
FIG 2 Observed drug concentrations versus population predicted concentrations for eight models of the population pharmacokinetics models of tobramycin.
The M numbers represent the models described in Table 1.
TABLE 3 Predictive performance of published pharmacokinetic models of tobramycin, including ME, MRE, and RMSE, and results of simulation-
based npde diagnosticsa
Model no. (reference)
Bias and imprecision npde diagnostics
ME (mg/liter)b MRE (%)b
RMSE
(%) Mean Variance Skewness Kurtosis
P value
Wilcoxon
signed-rank test
Fisher test
for variance
Shapiro-Wilks
test
Adult and pediatric
patients
M1 (32) 3.0 (2.5,3.5) 75.3 (62.5, 88.2) 131.1 0.3 1.5 0.5 0.1 0.0 0.0 0.0
M2 (36) 1.0 (0.5,1.4) 19.2 (12.7, 25.7) 57.6 0.1 0.7 0.1 1.2 0.2 0.0 0.0
Pediatric patients
M3 (33) 12.1 (11.4, 12.7) 274.1 (240.4, 307.7) 392.4 1.1 1.1 0.2 0.6 0.0 0.5 0.0
M4 (32) 2.4 (2.0, 2.9) 71.5 (58.6, 84.4) 129.1 0.3 1.6 0.4 0.3 0.0 0.0 0.0
M5 (31) 6.0 (5.3, 6.6) 222.0 (187.2, 256.8) 365.9 0.9 2.3 0.2 0.7 0.0 0.0 0.0
M6 (11) 0.4 (0.7, 0.01) 4.9 (0.8, 10.6) 47.8 0.0 0.8 0.0 1.6 0.5 0.0 0.0
M7 (3) 1.8 (1.4, 2.3) 29.4 (22.2, 36.6) 66.9 0.1 0.7 0.1 1.2 0.2 0.0 0.0
M8 (41) 4.0 (4.6,3.4) 20.2 (27.9,12.5) 67.4 0.2 2.7 0.0 1.3 0.0 0.0 0.0
a Presented are summary statistics for the distribution of the npde’s: mean, variance, skewness, and kurtosis. The expected value of these four variables for N(0, 1) are, respectively,
0, 1, 0, and 0. Further results for (i) a Wilcoxon signed-rank test, to test whether the mean is significantly different from 0, (ii) a Fisher test for variance, to test whether the variance
is significantly different from 1, and (iii) a Shapiro-Wilks test, to test whether the distribution is significantly different from a normal distribution, are presented (30).
b Data in parentheses are 95% confidence intervals.
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els and an improved npde-versus-time after dosing statistics com-
pared to those of the other models. Several models, in particular,
models with a one-compartment distribution (four out of five
models), showedweaknesses inmodel fit when the simulationwas
examined.
DISCUSSION
This study is the first to reviewmodels of the population pharma-
cokinetics of tobramycin in pediatric patients currently published
in the literature and to systemically externally evaluate the predic-
tive performance of these models. Population pharmacokinetic
models 2, 6, and 7 stood out as having the best predictive perfor-
mance across all the different tests. These models displayed visu-
ally favorable observed concentration-versus-population pre-
dicted concentration plots, with model 6 appearing to be the best.
The same models were distinguished in the numerical predictive
performance assessment, ranking in the top three for at least two
of the three criteria: ME, MRE, and RMSE. They also stood out as
being the best using simulation-based diagnostics.
Model 2 (36), which was developed using the largest data set
andwhich included the greatest number of covariate influences on
pharmacokinetic parameters, was consistently among the top
three models for all assessments. This model’s distinguished per-
formance likely suggests that large population studies which in-
clude a number of covariate influences will likely have a better
predictive ability with future patients. A trend toward an im-
proved predictive performance was noted for models with a
two-compartment disposition rather than a one-compartment
disposition, with the two best models (M2 and M6) being two-
compartmentmodels and the two least favorablemodels (M3 and
M5) being one-compartment models. A multiple-compartment
distribution likely better characterizes the tissue accumulation re-
ported for tobramycin (37). Distinguishing between distribution
and elimination processes is, however, highly dependent on the
sampling scheme (6, 38). It can be seen that model 3, a one-com-
partmentmodel developedwith data from a pediatric cystic fibro-
sis population, struggles to predict peak concentrations (Fig. 3; see
also Fig. S2 in the supplemental material). All models incorpo-
rated the influence of body size on either CL or V; this makes
sense, as tobramycin distributes into extracellular fluid, which
tends to increase with increasing patient size (39). Models 2, 3, 6,
7, and 8 used a nonlinear function to describe the relationship
between drug clearance and patient size; while three of these were
the best-performing models, the others were the worst-perform-
ing models. Only one of the top three models included the influ-
ence of a renal function descriptor on tobramycin clearance,
which is surprising, as tobramycin is largely renally eliminated
(40). However, most studies were based on patients with normal
to moderately impaired renal function, and hence, the influence
of renal function on drug clearancemay not be significant enough
to be detected in this circumstance. Similarly, most patients in the
validation data set had normal to only moderately impaired renal
function, so the inclusion or the lack of inclusion of renal function
in the population model may be of little importance in this cir-
cumstance.
Some models may have performed poorly, as they were not
externally validated with data from a population similar to that
with which they were developed. The validation data set did not
include any ICU patients and included only 3 infants between the
ages of 5 and 15weeks.Model 8 (41)was developedwith data from
ICU patients who were predominately less than 1 month old and
reported the large pharmacokinetic variability commonly seen in
FIG 3 Visual predictive checks performed using the identified models (M1 to M8; Table 1) and the validation data set. Here, the 95th and the 5th percentiles
(broken lines) and the 50th percentile (continuous lines) of the validation data concentrations (red) and themodel-predicted concentrations (black) on the x axis
are plotted versus time after dosing (hours) on the y axis. The shaded areas present the binning and the 95% prediction interval.
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this population (39, 42). Similarly, model 5 (31) was developed
using data from neonates, which may exhibit pharmacokinetics
different from those exhibited by older pediatric patients (31, 41).
This model was the only one originally externally validated with
data from a patient population very similar to the populationwith
which it was developed, but it did not perform sowell in this study.
The underprediction of particular peak tobramycin concentra-
tions (Fig. 3; see also Fig. S2 in the supplemental material) seen
with these models might be due to the larger volume of distribu-
tion (on a per-kilogram basis) often seen in individuals and neo-
nates in ICUs than in other populations.
For all models tested, RMSE was 30%. This suggests that
knowledge of typical pharmacokinetic behavior and patient cova-
riate values alone without feedback concentration measurements
from individual patients is not sufficient to make precise predic-
tions. This could improve by incorporation of themodel in Bayes-
ian forecasting software, which would allow feedback from subse-
quent measurements and the further individualization of the
parameters (43).
There were limitations associated with this study. One weak-
ness of the analysis is the limited size and heterogeneity of the
external data set used for validation. Data came only from cystic
fibrosis patients, and few patients were neonates or had renal im-
pairment. As with any study involving retrospective data collec-
tion, uncertainty is associated with data records (21). Interpreta-
tion of the published models was complicated in some instances
where exact methodologies were not clearly described and details
were absent. Three of the eight models did not report any RUV or
BSV values. Substitute values were added for application of the
models, but this may have altered the ability of models 1, 3, and 4
to accurately predict tobramycin concentrations. Furthermore,
some patients contributed more data to the validation data set
than others, and all observations were treated independently in
the analysis, which can result in bias toward results for patients
that contributed larger amounts of data. Of note, for 56% of pa-
tients, at least one SCRmeasurement was recorded as30 mol/
liter, which is below the LOQ of the assay used to measure this
compound. In order to be able to partly utilize this information,
these measurements were fixed to 29 mol/liter, as no other data
were available. This, however, may have influenced the predictive
performance of the models that included renal function as a co-
variate.
This study externally evaluated eight published models of the
population pharmacokinetics of tobramycin with newly collected
clinical data. Several of the published models were found to have
reasonably low levels of bias but a greater degree of imprecision.
This suggests that knowledge of typical pharmacokinetic behavior
and patient covariate values alone without feedback concentra-
tion measurements from individual patients is not sufficient to
make precise predictions.
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